Premium
Pain Related Behaviors in Mice Expressing Sickle Hemoglobin: Modulation by Bivalent Ligands
Author(s) -
RodríguezDeliz Carla Leticia,
Puig Guillermo,
Cataldo Giuseppe,
Simone Donald
Publication year - 2016
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.30.1_supplement.993.12
Subject(s) - medicine , sickle cell trait , disease , genetically modified mouse , hyperalgesia , threshold of pain , hemoglobin , acute chest syndrome , sickle cell anemia , transgene , immunology , anesthesia , gastroenterology , gene , nociception , receptor , biology , genetics
Sickle cell disease (SCD) is a genetic disorder that produces abnormal hemoglobin, leading to vaso‐occlusion. The hallmark of this condition is pain. Little is known about the mechanisms of SCD, therefore, treatment remains inefficient. Several types of transgenic mice have been developed in order to study therapeutic options for SCD, including the Townes mice. In this study, we aimed to characterize pain‐related behaviors in the Townes sickle mouse, as well as identify the onset of SCD‐associated hyperalgesia. In addition, we aimed to study the effect of a new drug, MCC22, on such pain‐related behaviors. For this, we measured paw withdrawal frequency (PWF) and mechanical threshold, as well as grip force to compare between control (AA), sickle trait (AS) and sickle cell (SS) mice. MCC22 was administrated through intraperitoneal (IP) injection and the mechanical tests were conducted at 15, 30 and 60 minutes to evaluate its effects. We observed that sickle mice had significantly higher PWF and lower thresholds and grip force when compared to AA and AS mice. Administration of MCC22 reduced PWF in SS mice. Decreases in relevant pain behaviors suggest that MCC22 may prove to be a novel effective therapeutic in SCD.